Mohamed Shahin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohamed Shahin has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Ahmed H. Abdelazim
Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Al- Azhar University, Cairo, Egypt
3 shared publications - Sherif Ramzy
Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Al- Azhar University, Nasr City, Egypt
3 shared publications - Ahmed A Almrasy
Al-Azhar University, Faculty of Pharmacy, Pharmaceutical Analytical Chemistry Department , 11751 Nasr City, Cairo, Egypt
1 shared publication - Ahmed H. Abdel-Monem
Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Al-Azhar University, 11751 Nasr City, Cairo, Egypt
1 shared publication - Ashraf Abdel-Fattah
Pharmaceutical Analytical Chemistry Department, Faculty of Pharmacy, Al-Azhar University, 11751 Nasr City, Cairo, Egypt
1 shared publication
Latest Publications
- 2 May 2022
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
- Vol. 105 (5) , 1479-1483
Quantitative Spectrophotometric Analysis of Celecoxib and Tramadol in Their Multimodal Analgesia Combination Tablets
Background: Pain is a global, complex health problem that includes physical, emotional, and social components. The pain management process has many goals, including patient satisfaction, reducing clinical complications, and lowering costs. The physician describes pain medications in terms of the proven cause and classification of the severity of the pain. The combination of celecoxib and tramadol was recently approved by the Food and Drug Administration (FDA) in October 2021 for the treatment of acute pain in adults. Objective: This paper presents the first published quantitative analytical methods for celecoxib and tramadol. Methods: The UV absorption spectra of celecoxib and tramadol showed strong overlap. Mathematical simultaneous equation and ratio difference methods were developed to resolve the spectral overlap and quantify the drugs in the combination mixture. In the simultaneous equation method, the absorbance and absorptivity values at 252 and 217 nm were used to construct two mathematical equations that were used for the simultaneous mathematical quantification of the above drugs. The mathematical manipulation of the ratio difference based on the calculation of the differences in the amplitude values between 250 and 280 nm enabled the quantitative analysis of celecoxib, and the differences in the amplitude values between 221 and 272 nm enabled the quantitative analysis of tramadol. Results: The proposed methods were successfully applied to the selective quantitative analysis of celecoxib and tramadol in the synthetic mixtures and in the pharmaceutical tablets without interference from the tablet additives. Conclusions: The applied methods demonstrated good linearity in the concentration range of 1–20 µg/mL and 3–45 µg/mL for celecoxib and tramadol, respectively, with acceptable accuracy and precision. The methods were found to be sensitive with LOD values of 0.183 µg/mL and 0.626 µg/mL for celecoxib and tramadol, respectively, in simultaneous equation method and of 0.275 µg/mL and 0.772 µg/mL for celecoxib and tramadol, respectively, in ratio difference method. Highlights: The first established simple and validated UV spectrophotometric methods were described for concurrent quantification of the celecoxib and tramadol in their recently approved pharmaceutical formulation.
- 2 May 2022
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
- Vol. 105 (5) , 1479-1483
Quantitative Spectrophotometric Analysis of Celecoxib and Tramadol in Their Multimodal Analgesia Combination Tablets
Background: Pain is a global, complex health problem that includes physical, emotional, and social components. The pain management process has many goals, including patient satisfaction, reducing clinical complications, and lowering costs. The physician describes pain medications in terms of the proven cause and classification of the severity of the pain. The combination of celecoxib and tramadol was recently approved by the Food and Drug Administration (FDA) in October 2021 for the treatment of acute pain in adults. Objective: This paper presents the first published quantitative analytical methods for celecoxib and tramadol. Methods: The UV absorption spectra of celecoxib and tramadol showed strong overlap. Mathematical simultaneous equation and ratio difference methods were developed to resolve the spectral overlap and quantify the drugs in the combination mixture. In the simultaneous equation method, the absorbance and absorptivity values at 252 and 217 nm were used to construct two mathematical equations that were used for the simultaneous mathematical quantification of the above drugs. The mathematical manipulation of the ratio difference based on the calculation of the differences in the amplitude values between 250 and 280 nm enabled the quantitative analysis of celecoxib, and the differences in the amplitude values between 221 and 272 nm enabled the quantitative analysis of tramadol. Results: The proposed methods were successfully applied to the selective quantitative analysis of celecoxib and tramadol in the synthetic mixtures and in the pharmaceutical tablets without interference from the tablet additives. Conclusions: The applied methods demonstrated good linearity in the concentration range of 1–20 µg/mL and 3–45 µg/mL for celecoxib and tramadol, respectively, with acceptable accuracy and precision. The methods were found to be sensitive with LOD values of 0.183 µg/mL and 0.626 µg/mL for celecoxib and tramadol, respectively, in simultaneous equation method and of 0.275 µg/mL and 0.772 µg/mL for celecoxib and tramadol, respectively, in ratio difference method. Highlights: The first established simple and validated UV spectrophotometric methods were described for concurrent quantification of the celecoxib and tramadol in their recently approved pharmaceutical formulation.
- 30 March 2022
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
- Vol. 105 (5) , 1475-1478
Application of Different UV Spectrophotometric Methods for Quantitative Analysis of Acotiamide and Esomeprazole
Background: Acotiamide and esomeprazole are co-administrated and prescribed for gastrointestinal disorder diseases.Objective: Development of the first UV spectrophotometric methods for the quantitative analysis of acotiamide and esomeprazole in their mixture.Methods: The UV absorption spectra of acotiamide and esomeprazole showed severe overlapping. To solve the spectral overlapping and quantify the studied drugs in their mixture, simultaneous equation and ratio difference methods were developed. For simultaneous equation method, the absorbance and absorptivity values at 279 and 302 nm were used to construct two mathematical equations applied for the spectrophotometric assay of the cited drugs. Ratio difference spectra manipulated method was developed and enabled successful quantitative determination of acotiamide and esomeprazole. The differences in the amplitude values between 280 and 260 nm enabled estimation of acotiamide, and the differences in the amplitude values between 303 and 282 nm enabled estimation of esomeprazole.Results: The proposed methods succeeded to quantify acotiamide and esomeprazole in the synthetic mixtures and in their pharmaceutical tablets without any interference from each other or from tablet additives.Conclusions: The applied methods demonstrated good linearity in the concentration range of 2–30 µg/mL and 2–20 µg/mL for acotiamide and esomeprazole, respectively, with acceptable accuracy and precision. The methods were found to be sensitive with LOD values of 0.336 µg/mL and 0.332 µg/mL for acotiamide and esomeprazole, respectively, in simultaneous equation method and of 0.410 µg/mL and 0.333 µg/mL for acotiamide and esomeprazole, respectively, in ratio difference method.Highlights: Simple and validated UV spectrophotometric methods were described for selective quantification of the acotiamide and esomeprazole in their mixture.
- 30 March 2022
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
- Vol. 105 (5) , 1475-1478
Application of Different UV Spectrophotometric Methods for Quantitative Analysis of Acotiamide and Esomeprazole
Background: Acotiamide and esomeprazole are co-administrated and prescribed for gastrointestinal disorder diseases.Objective: Development of the first UV spectrophotometric methods for the quantitative analysis of acotiamide and esomeprazole in their mixture.Methods: The UV absorption spectra of acotiamide and esomeprazole showed severe overlapping. To solve the spectral overlapping and quantify the studied drugs in their mixture, simultaneous equation and ratio difference methods were developed. For simultaneous equation method, the absorbance and absorptivity values at 279 and 302 nm were used to construct two mathematical equations applied for the spectrophotometric assay of the cited drugs. Ratio difference spectra manipulated method was developed and enabled successful quantitative determination of acotiamide and esomeprazole. The differences in the amplitude values between 280 and 260 nm enabled estimation of acotiamide, and the differences in the amplitude values between 303 and 282 nm enabled estimation of esomeprazole.Results: The proposed methods succeeded to quantify acotiamide and esomeprazole in the synthetic mixtures and in their pharmaceutical tablets without any interference from each other or from tablet additives.Conclusions: The applied methods demonstrated good linearity in the concentration range of 2–30 µg/mL and 2–20 µg/mL for acotiamide and esomeprazole, respectively, with acceptable accuracy and precision. The methods were found to be sensitive with LOD values of 0.336 µg/mL and 0.332 µg/mL for acotiamide and esomeprazole, respectively, in simultaneous equation method and of 0.410 µg/mL and 0.333 µg/mL for acotiamide and esomeprazole, respectively, in ratio difference method.Highlights: Simple and validated UV spectrophotometric methods were described for selective quantification of the acotiamide and esomeprazole in their mixture.
- 15 February 2022
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
- Vol. 105 (4) , 1200-1204
Quantitative Analysis of Two Pharmaceutical Combinations Containing Amlodipine with Either Bisoprolol or Candesartan Using Different UV Spectrophotometric Methods
Background: Two fixed-dose combination tablets of amlodipine (AML) with bisoprolol (BIS) and amlodipine with candesartan (CAN) were recently approved for the treatment of hypertension. Objective: Three UV spectrophotometric analytical methods were developed for the estimation of the above drugs in their combination mixtures. Methods: For the AML and BIS mixture, AML was quantified directly by a zero-order spectrophotometric method at 360 nm without interference from BIS, whereas BIS was quantified by the ratio difference (RD) spectrophotometric method by calculating the difference between the amplitude values of the ratio spectra at 226 and 215 nm. For the AML and CAN mixture, AML was quantified directly by a zero-order spectrophotometric method at 360 nm without interference from CAN, whereas CAN was quantified by the first derivative of ratio spectra method by measuring the amplitude values of the derived spectra at 259 nm.BIS) Results: The proposed methods were successfully applied for quantitative analysis of AML with BIS and AML with CAN in their synthetic laboratory-prepared mixtures and pharmaceutical tablets with acceptable results in terms of accuracy and precision. Conclusion and Highlights: Simple, accurate, and environmentally friendly spectrophotometric methods were described for selective determination of the investigated drugs in their fixed-dose combinations.
- 15 February 2022
- Published by Oxford University Press (OUP) in Journal of AOAC INTERNATIONAL
- Vol. 105 (4) , 1200-1204
Quantitative Analysis of Two Pharmaceutical Combinations Containing Amlodipine with Either Bisoprolol or Candesartan Using Different UV Spectrophotometric Methods
Background: Two fixed-dose combination tablets of amlodipine (AML) with bisoprolol (BIS) and amlodipine with candesartan (CAN) were recently approved for the treatment of hypertension. Objective: Three UV spectrophotometric analytical methods were developed for the estimation of the above drugs in their combination mixtures. Methods: For the AML and BIS mixture, AML was quantified directly by a zero-order spectrophotometric method at 360 nm without interference from BIS, whereas BIS was quantified by the ratio difference (RD) spectrophotometric method by calculating the difference between the amplitude values of the ratio spectra at 226 and 215 nm. For the AML and CAN mixture, AML was quantified directly by a zero-order spectrophotometric method at 360 nm without interference from CAN, whereas CAN was quantified by the first derivative of ratio spectra method by measuring the amplitude values of the derived spectra at 259 nm.BIS) Results: The proposed methods were successfully applied for quantitative analysis of AML with BIS and AML with CAN in their synthetic laboratory-prepared mixtures and pharmaceutical tablets with acceptable results in terms of accuracy and precision. Conclusion and Highlights: Simple, accurate, and environmentally friendly spectrophotometric methods were described for selective determination of the investigated drugs in their fixed-dose combinations.